SERA discloses PRIME prematurity study peer-reviewed publication

Rhea-AI Filing Summary

Sera Prognostics, Inc. filed a current report to share that findings from its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (“PRIME”) study have been accepted for publication in a peer-reviewed journal. The company disclosed this information under a Regulation FD disclosure, indicating it was also announced in a press release dated November 24, 2025, furnished as an exhibit to the report.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000153496900015349692025-11-242025-11-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 24, 2025

Sera Prognostics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40606	26-1911522
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2749 East Parleys Way Suite 200
Salt Lake City, Utah				84109
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (801) 990-0520

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share		SERA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 24, 2025, Sera Prognostics, Inc. (the “Company”) issued a press release announcing that the findings of the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (“PRIME”) study were accepted for publication in a peer-reviewed journal. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information contained in Item 7.01, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except to the extent required by applicable law or regulation.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press release dated November 24, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SERA PROGNOSTICS, INC.
Date:	November 24, 2025	By:	/s/ Austin Aerts
			Austin Aerts Chief Financial Officer

FAQ

What did Sera Prognostics (SERA) announce in this 8-K filing?

Sera Prognostics reported that the findings of its PRIME study were accepted for publication in a peer-reviewed journal and announced this via a press release furnished with the filing.

What is the PRIME study mentioned by Sera Prognostics?

The PRIME study is described as Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs, and its findings have been accepted for publication in a peer-reviewed journal.

When did Sera Prognostics issue the press release about the PRIME study?

Sera Prognostics issued the press release on November 24, 2025, and furnished it as Exhibit 99.1 to the report.

Does this SERA 8-K include financial results or earnings data?

No, this report focuses on a Regulation FD disclosure about the PRIME study publication and lists the related press release as an exhibit, without presenting financial results or earnings metrics.

Is the PRIME study press release considered filed for liability purposes?

The company states that the information in Item 7.01, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, except as required by law or regulation.

Who signed the Sera Prognostics 8-K related to the PRIME study?

The report was signed on behalf of Sera Prognostics, Inc. by Austin Aerts, Chief Financial Officer.